Ketamine One Appoints Joe Ramelli as Its New Chief


VANCOUVER, British Columbia, Dec. 14, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that Joe Ramelli has been appointed as Ketamine One’s new Chief Financial Officer (“CFO”) effective December 14, 2021, subject to the final acceptance of the NEO Exchange. Mr. Ramelli holds a Bachelor of Arts (with honours) in Business Economics from the University of California, Santa Barbara and has also attended the Director Education and Certification Program at the UCLA’s Anderson School of Management.

Joe has nearly 30 years of experience in the public markets and Biotechnology, Biopharmaceutical and Financial Services industries. He is a seasoned investor and consultant who specializes in business strategic planning and development, capital raising, talent acquisition, and corporate governance. Mr. Ramelli served as Interim CFO at ValenzaBio, a privately held biopharmaceutical company, from its inception, where he established and grew all the finance functions of the company. During Joe’s tenure at ValenzaBio, the team closed a USD 15 million seed funding round and a USD 70 million Series A subsequent round that was led by Fidelity Management & Research, LLC.

Ketamine One’s former CFO, Peter Nguyen, has amicably agreed to depart the Company in order to facilitate Mr. Ramelli’s transition into the role as Ketamine One intends to confidentially submit a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to a potential USD 20 million initial public offering of its common shares in the United States. Peter has also resigned from the Company’s Board of Directors effective December 13, 2021. Ketamine One thanks Mr. Nguyen for his service on its Board of Directors.

Management Commentary

“On behalf of the Board of Directors, I am pleased to welcome Joe to Ketamine One’s management team as we embark on the Company’s exciting next chapter. Mr. Ramelli comes to our organization as a highly recommended professional and we are looking forward to learning from his expertise,” said Adam Deffett, Interim CEO of Ketamine One. “I would like to thank Peter for his service to Ketamine One and I appreciate his efforts to help the Company become a public issuer. I and the team wish him well on his future endeavours,” added Mr. Deffett.

ABOUT KETAMINE ONE

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

On behalf of:

KETAMINE ONE

Adam Deffett
Adam Deffett, Interim CEO

For further information, please contact:

Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

SOURCE: KetamineOne Capital Limited

Previous HCMC Announces Filing of Appeal to Ruling in Case Against
Next Skylight Health Group Completes Divestiture of Legacy